Clinica Chimica Acta:甲亢患者磷脂酰丝氨酸特异性磷脂酶A1水平升高?

2020-04-13 MedSci原创 MedSci原创

虽然有报道称,在免疫系统中的溶磷脂质介导剂---溶磷脂质丝氨酸的特异性受体中存在单核苷酸多态性,但溶磷脂质丝氨酸和甲状腺疾病之间的关联性仍有待阐明。

虽然有报道称,在免疫系统中的溶磷脂质介导剂---溶磷脂质丝氨酸的特异性受体中存在单核苷酸多态性,但溶磷脂质丝氨酸和甲状腺疾病之间的关联性仍有待阐明。因此,我们旨在研究磷脂酰丝氨酸特异性磷脂酶A1 (PS-PLA1)的水平与甲状腺疾病的关系。我们测量了不同甲状腺疾病患者(n = 120)和正常受试者(n = 58)的血清PS-PLA1水平。

我们观察到,Graves病、亚急性甲状腺炎或沉默性甲状腺炎患者血清PS-PLA1水平较高,而甲状腺功能减退患者血清PS-PLA1水平不受调节。血清PS-PLA1水平与甲状腺激素水平密切相关,在Graves病患者中尤为明显。此外,我们发现Graves病患者血清中PS-PLA1水平经抗甲状腺药物治疗后降低,且PS-PLA1的变化与甲状腺激素的变化密切相关。

这些结果提示,PS-PLA1可能是治疗甲状腺功能亢进症,特别是Graves病的一个新的靶点,其测定可能作为甲状腺功能的辅助诊断试验。

原始出处:

Kazuki Nakawatari,Makoto Kurano,Elevated phosphatidylserine-specific phospholipase A1 level in hyperthyroidism

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849918, encodeId=79dc184991846, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Oct 01 21:20:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899372, encodeId=6cc518993e276, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 03 08:20:04 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968566, encodeId=afd3196856652, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Dec 31 16:20:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-10-01 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849918, encodeId=79dc184991846, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Oct 01 21:20:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899372, encodeId=6cc518993e276, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 03 08:20:04 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968566, encodeId=afd3196856652, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Dec 31 16:20:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849918, encodeId=79dc184991846, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Oct 01 21:20:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899372, encodeId=6cc518993e276, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 03 08:20:04 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968566, encodeId=afd3196856652, content=<a href='/topic/show?id=2e902103631' target=_blank style='color:#2F92EE;'>#丝氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21036, encryptionId=2e902103631, topicName=丝氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Dec 31 16:20:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]